Home
Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. Market Share Analysis for February 2026

Mirati Therapeutics, Inc. is an American targeted oncology company that focuses on the development of cancer therapeutics. Bristol Myers Squibb acquired the company in January 2024.

Health > Biotechnology and Pharmaceuticals

Domainmirati.com

Year Founded1995

Employees501 - 1000

Annual Revenue$50M - $75M

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. (including company regionals)

mirati.com

See more website traffic and engagement information

Mirati Therapeutics, Inc. Revenue up to February 2026 is 50M - 75M

revenue generated by Mirati Therapeutics, Inc. top domains

Mirati Therapeutics, Inc. top domains revenue over 3 years

Revenue for Mirati Therapeutics, Inc. top domains

mirati.com50M - 75M

See more with Sales Intelligence

Total visits to Mirati Therapeutics, Inc.'s top domains

Understand Mirati Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Mirati Therapeutics, Inc.'s top domains

Analyze Mirati Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Mirati Therapeutics, Inc.'s top domains

See how Mirati Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Mirati Therapeutics, Inc. top competitors by domain

Top similar sites in February 2026, ranked by their affinity

meipharma.comCompany NameMEI PharmaEmployees51 - 200HQUnited States, California, San DiegoAnnual revenue$50M - $75MTotal visits1.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Mirati Therapeutics, Inc.

These are the website technologies, by industry, used by Mirati Therapeutics, Inc. top domains

Advertising (10)

DoubleClick

Conversion & Analytics (6)

Google Analytics

Widget (5)

Twemoji

Audio Video Media (4)

YouTube

More Technologies

11

See all

News & Signals from Mirati Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsVieira left Mirati Therapeutics, Inc. as Senior Vice President of U.S. Commercial on Jan 29th '24.Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month.

NewsTP Therapeutics, Inc. acquires Mirati Therapeutics, Inc..NEW YORK - Bristol Myers Squibb is focusing on diversifying its oncology product portfolio with its planned acquisition of Mirati Therapeutics and the forthcoming approval decision for the tyrosine kinase inhibitor repotrectinib it acquired from Turning Point Therapeutics.

NewsBMS acquires Mirati Therapeutics, Inc. for $4.8B.BMS buys Mirati for $4.8B; Pfizer to slash cost; Q&A with vertex CSO; Alnylam's onpattro setback; and more.